Market Signal Briefing

Jupiter (JUP) price has entered a make-or-break zone after months of steady decline, which is now slowly gaining attention. Currently trading around $0.1464, the crypto is down by more than 4% in the past 24 hours, and more than 90% from the highs. The chart suggests that the token has been under persistent distribution phase, which is believed to be fading. With this, the JUP price is pressing up against an area where reactions have mattered in the past. 

With volatility compressing and technicals heading towards the reversal zone, Jupiter is believed to be entering a decisive phase. Now, traders are wondering whether this consolidation will result in a rebound or begin another leg lower.

On the weekly timeframe, it shows a transition from expansion to contraction. Price previously broke down from a major supply zone between $0.55 and $0.65, an area that has since flipped into firm resistance. Since that rejection, JUP has followed a clean bearish structure, printing a sequence of lower highs and lower lows. The trading activity has steadily thinned out, suggesting waning participation often appears when a market is waiting for its next catalyst.

The RSI is hovering around 30–33, close to oversold but without a clear bullish divergence, which means downside pressure hasn’t fully burned off yet. MACD remains below the zero line and is beginning to flatten, hinting at stabilization rather than an outright reversal. Price is currently holding just above the $0.13–$0.15 demand zone, an area that previously acted as a base during early consolidation. A clean weekly close below $0.14 would weaken that structure and likely expose JUP to a deeper slide toward $0.10–$0.08, where liquidity is thinner but historically reactive.

On the upside, any bounce is likely to face resistance near $0.20–$0.24, with heavier supply waiting closer to $0.33. Only a sustained reclaim above $0.35 would meaningfully neutralize the broader bearish structure.

Jupiter (JUP) price is still in a range-to-breakdown environment, not a confirmed bottoming phase. Holding above $0.14 keeps short-term relief bounces on the table, but a loss of that level would likely accelerate downside toward $0.10.   

Trust with CoinPedia:CoinPedia has been delivering accurate and timely cryptocurrency and blockchain updates since 2017. All content is created by our expert panel of analysts and journalists, following strict Editorial Guidelines based on E-E-A-T (Experience, Expertise, Authoritativeness, Trustworthiness). Every article is fact-checked against reputable sources to ensure accuracy, transparency, and reliability. Our review policy guarantees unbiased evaluations when recommending exchanges, platforms, or tools. We strive to provide timely updates about everything crypto & blockchain, right from startups to industry majors.

Investment Disclaimer:All opinions and insights shared represent the author's own views on current market conditions. Please do your own research before making investment decisions. Neither the writer nor the publication assumes responsibility for your financial choices.

Sponsored and Advertisements:Sponsored content and affiliate links may appear on our site. Advertisements are marked clearly, and our editorial content remains entirely independent from our ad partners.

Canaan's hardware shipments hit a record level in the quarter, helped by large North American mining orders.

📊
No votes yet – Be the first to vote

XRP crashed hard last week. The February 3 selloff sent retail traders into full panic mode while crypto whales swooped in to grab millions of tokens at bargain prices.

The crypto market got hammered across the board, with Bitcoin and Ethereum taking serious hits too. But the whale response was pretty much textbook – they saw blood in the streets and started buying like crazy. XRP’s price dropped over 20% in just a few hours, which scared the hell out of smaller investors who’d been holding bags since the last bull run. These retail folks couldn’t dump their coins fast enough, creating the perfect storm for institutional players to load up.

Whale Alert caught some wild transactions.

One wallet alone grabbed over 100 million XRP tokens worth around $42 million. That’s not pocket change – that’s serious conviction buying from someone who thinks XRP’s going way higher once this mess clears up. The data doesn’t lie about what big money really thinks when prices crater.

Market-wide chaos made everything worse, with regulatory pressure and macro uncertainty piling on. Retail investors got spooked and kept selling, pushing prices down even further. The fear was real – you could feel it in every trading chat and crypto forum. Small holders who bought near previous highs were staring at massive losses and decided to cut their losses before things got uglier.

But whales see opportunity where others see disaster. These institutional buyers clearly believe XRP’s technology and adoption potential will win out long-term, even with all the current volatility and legal drama hanging over everything.

Trading volume went absolutely bonkers during the selloff. Exchanges reported crazy activity levels as panic selling met strategic accumulation. The divergence was stark – small fish swimming for the exits while big fish swam against the current. Coinbase and Binance both saw XRP trading spike to levels not seen in months.

Investor sentiment took a beating. Retail traders who got into crypto during calmer times weren’t ready for this kind of volatility. Meanwhile, seasoned players and institutions treated the chaos like a clearance sale. The difference in risk tolerance was pretty obvious – newbies running scared while veterans backed up the truck. This follows earlier reporting on XRP Holders Dump Coins as Key.

XRP faces major headwinds ahead. The SEC case against Ripple still hangs over everything like a dark cloud. Nobody knows when that legal battle will wrap up or how it’ll turn out. A win for Ripple could send XRP to the moon. A loss could crater the price even more. The uncertainty keeps everyone on edge.

Legal experts can’t agree on which way the case will go. Some think Ripple has a strong defense. Others worry the SEC has enough ammunition to win. The court filings keep coming but no clear resolution is in sight. Both sides seem dug in for a long fight.

Market analysts are glued to every development in the case. Any hint of progress could trigger massive price swings in either direction. The legal uncertainty makes XRP one of the most unpredictable major cryptos right now.

For now, XRP remains under serious pressure. The token’s price keeps bouncing around based on broader market moves and shifting investor sentiment. But that whale buying activity suggests some smart money sees the current dip as a golden opportunity rather than a reason to panic.

Binance reported XRP trading volume hit over $1 billion in 24 hours on February 5. That’s massive interest and activity around the asset as traders tried to capitalize on wild price swings. XRP ranked among the top-traded coins on the platform during this volatile period. Related coverage: Goldman Sachs Slams False .5 Trillion.

Ripple CEO Brad Garlinghouse spoke up on February 4 about the market conditions. He said the company stays committed to fighting the SEC and improving cross-border payments no matter what. Garlinghouse tried to calm nerves: “We remain focused on our mission regardless of current market turmoil.”

Chainalysis dropped some interesting data as things settled down. Whale accounts now control roughly 45% of total XRP supply. That concentration gives big holders serious power to move markets through their trading decisions. When whales decide to buy or sell, regular investors feel it.

The SEC case timeline remains murky. No new updates emerged as of February 6 about trial dates or potential settlements. The lack of clarity keeps market participants guessing about what comes next. Everyone’s waiting for some kind of resolution that could dramatically impact XRP’s future price action.

The broader crypto market’s February selloff coincided with several macroeconomic factors that amplified selling pressure. Federal Reserve officials had recently signaled potential interest rate adjustments, while inflation data remained stubbornly high. These conditions typically drive investors away from riskier assets like cryptocurrencies toward traditional safe havens.

Several major crypto funds disclosed their February trading activity in recent SEC filings. Grayscale and Pantera Capital both reported significant XRP accumulation during the price dip, with combined purchases exceeding $15 million. Their moves mirror the whale behavior seen on-chain, suggesting institutional consensus about XRP’s undervaluation despite ongoing regulatory challenges.

Post Views: 1

Cover image via U.Today Disclaimer: The opinions expressed by our writers are their own and do not represent the views of U.Today. The financial and market information provided on U.Today is intended for informational purposes only. U.Today is not liable for any financial losses incurred while trading cryptocurrencies. Conduct your own research by contacting financial experts before making any investment decisions. We believe that all content is accurate as of the date of publication, but certain offers mentioned may no longer be available.

Bulls are not ready yet to seize the initiative, and most of the coins keep trading in the green zone, according to CoinMarketCap.

Top coins by CoinMarketCapSOL/USDThe rate of Solana (SOL) has declined by 1.46% over the last 24 hours.

Image by TradingViewOn the hourly chart, the price of SOL is looking bearish as the rate has not bounced back far from the support at $83.69. If bulls cannot seize the initiative, one can expect a level breakout, followed by an ongoing decline to the $83 mark.

Image by TradingViewOn the longer time frame, the rate of SOL is also going down after a failed attempt to fix above the $90 area. 

You Might Also Like

If the daily bar closes around the current prices or below, traders may witness a test of the $80 range over the next few days.

Image by TradingViewFrom the midterm point of view, there are no reversal signals yet. The rate of SOL is in the middle of the channel, which means traders are unlikely to see increased volatility soon.

SOL is trading at $83.82 at press time.

Ethereum's MVRV Z score has dropped into a “capitulation zone,” according to analyst Joao Wedson, who shared an Alphafractal chart dated Feb. 9. The chart tracks Ethereum’s price in black and the MVRV Z score in blue, a measure that compares market value to realized value and then standardizes the gap.

Ethereum MVRV Z Score Chart. Source: Alphafractal via Joao Wedson on X

Wedson said the most recent low reached -0.42. He also pointed to the deepest reading on record, -0.76, which he said printed in December 2018. As a result, he framed the current decline as clear stress, while he argued it still falls short of the intensity seen at major cycle bottoms in 2018 and 2022.

The chart shows prior capitulation stretches when the Z score slipped below zero and stayed compressed for long periods. Meanwhile, earlier cycle peaks lined up with sharp Z score spikes, which appeared during fast price expansions. That contrast is why the indicator often gets used as a valuation stress gauge rather than a short term timing tool.

Wedson described capitulation as a process, not a single moment. He said markets often attempt rebounds that fail, then grind lower as weaker holders exit and volatility clears out positioning. However, he added that history suggests the metric can still move deeper into negative territory before a structural low forms.

On the latest reading, the Z score sits near the lower band again while price remains well above the lowest levels shown on the long term chart. That combination supports his main point: Ethereum shows strain on chain, but the data does not yet mirror the most extreme washout phases from prior cycles.

Ethereum chart highlights 2.1K as key line for bounceEthereum’s ETHUSD chart showed price testing a long watched $2,100 area after a sharp drop, according to a TradingView snapshot shared by Daan Crypto Trades on X. The analyst said the $2.1K zone has acted as an important level “over the past few years” and added that bulls need to reclaim it for a relief bounce to keep going.

Ethereum U.S. Dollar Chart. Source: Daan Crypto Trades on X

The chart, dated Feb. 9, showed ETH opening near $2,038, trading up to about $2,101, and then slipping to around $2,011 before closing near $2,083. That left price below the $2.1K mark after the session’s attempt to push back above it faded.

When zoomed out, the same chart mapped repeated reactions around the low $2,000s during earlier swings, with multiple bounces and breakdowns clustering near that band. It also marked higher resistance zones above, including a broader mid $2,000s area and a prior range nearer the low $3,000s, which price would need to clear before revisiting the 2021 peak labeled near the top of the chart.

Daan Crypto Trades framed the $2.1K line as the near term decision point. If price retakes that level and holds, the move would support the idea that the drop reset the range rather than breaking it, while a failure to reclaim it would keep the rebound fragile and leave ETH trading under a level the market has repeatedly treated as a pivot.

Tue, 10/02/2026 - 16:01

In a fresh CNBC interview, Michael Saylor confirms Strategy will buy Bitcoin (BTC) every quarter, dismissing sell-off fears and explaining why volatility, digital credit and Wall Street adoption favor long-term exposure in the cryptocurrency.

Cover image via U.Today Michael Saylor took advantage of the wild Bitcoin market to make one of the clearest corporate moves of this cycle. During a recent CNBC interview, the Strategy executive chairman said the company plans to buy Bitcoin every quarter, no matter what the short-term price does. 

According to Saylor, Bitcoin is like digital capital that is built for higher volatility and higher long-term returns than gold, stocks or real estate. Recent dips do not change anything for people who are allocating capital over several years like Saylor; that is why concerns about forced selling are invalid. Even if it is 90%, or $8,000 BTC.

"I don't think it's going to zero"Michael Saylor did not hedge, soften, or change his position on Bitcoin during his latest CNBC appearance. But once again, he made it official, confirming that Strategy, the company formerly known as MicroStrategy, will be buying Bitcoin every quarter, and they will keep doing it indefinitely. 

HOT Stories

On a Squawk Box live, Saylor described Bitcoin as digital capital designed to move harder and outperform over long periods of time. That's is why, for him, the volatility of Bitcoin is not a flaw but a property that allows Bitcoin to outperform gold, stocks and real estate over time. 

Saylor said that he was not worried about the possibility of a prolonged downturn leading to liquidation despite the price of the cryptocurrency being down by about 50% from October highs. For the Strategy chairman, a 90% drawdown, or for example hitting $8,000 per BTC, is not a condition to sell anything out of the company's insane 714,644 BTC stash.

You Might Also Like

He said Strategy has multiple years of cash coverage and decades of Bitcoin-linked value relative to its dividend obligations and, despite all the turbulence of late 2025-early 2026, refinancing is still a good idea, while forced selling is only an issue when the time comes. The company's leverage, according to his accounting, is well below typical investment-grade standards.

Related articles

New analysis suggests macroeconomic forces are overtaking halvings as key drivers of Bitcoin price cycles.

Market Sentiment:

Bullish Bearish Neutral

Published: February 10, 2026 │ 4:00 PM GMT

Created by Kornelija Poderskytė from DailyCoin

Bitcoin’s price movements are increasingly tracking traditional business cycles rather than responding primarily to halving events, according to new macro-focused analysis.

Bitcoin researcher Sminston With, who holds a PhD in science and engineering, outlined the shift in a post on X. 

Sponsored

He argues that what began as a loose relationship has grown significantly stronger since 2016, to the point where the so-called “Bitcoin cycle” is now largely a reflection of broader economic conditions rather than an isolated crypto-driven phenomenon.

Bitcoin vs. Business Cycle… might be worth paying attention to. 🔍

The correlation was locked by 2016, and it's been strengthening ever since.

This is an overlay of the PMI onto Bitcoin's power law trend for better visualization.

(1/2) 🧵👇 pic.twitter.com/WFIZIH1aiE

— Sminston With 👁 (@sminston_with) February 9, 2026 Macro Signals Outpacing Halvings in Price ImpactThe analyst compared Bitcoin’s long-term price behavior with the overall health of the economy, using indicators such as the Purchasing Managers’ Index (PMI) to assess how economic conditions influence Bitcoin’s market cycles.

According to him, Bitcoin’s behavior shifted from weak associations to a strong alignment with the business cycle around 2016, a period that coincided with the cryptocurrency’s second halving. From that point onward, broader economic forces began to play a more decisive role in shaping price movements.

The correlation, Sminston notes, has continued to strengthen over time, suggesting that macroeconomic trends have become a dominant driver of Bitcoin bull runs. Periods of economic expansion tend to coincide with sustained rallies, while economic slowdowns are increasingly linked to price declines.

Visuals shared in the thread show PMI trends closely tracking Bitcoin’s price path, with expansions supporting rallies and contractions triggering corrections. 

At the same time, the analyst cautions that the relationship is not linear. The correlation can weaken temporarily during each cycle, typically easing until Bitcoin reaches a new all-time high before resuming its longer-term upward trend.

Why This MattersThe shift suggests that Bitcoin is no longer moving on its own, separate from the global economy. As more institutions enter the market through spot ETFs, corporate holdings, and regulated investment products, Bitcoin is becoming more influenced by interest rates, economic growth, and overall market liquidity. 

As a result, Bitcoin’s price cycles may start to look more like those of traditional risk assets, making broader economic signals just as important as crypto-specific events like halvings.

Dig into DailyCoin’s popular crypto news now:
Decentralized Milestone: Hyperliquid Overtakes Coinbase in Perp Trading
HBAR Pitched As “Invisible Plumbing” Of ‘Global Reset’

People Also Ask:What is a Bitcoin halving?

A Bitcoin halving is an event that occurs roughly every four years, reducing the number of new bitcoins miners receive by half. It historically influences Bitcoin’s price by tightening supply.

What does it mean that Bitcoin is following the business cycle?

It means Bitcoin’s price movements are increasingly linked to the overall economy. Economic expansions tend to coincide with price rallies, while contractions often lead to declines.

Why should investors care about this correlation?

If Bitcoin’s price is influenced by the economy, monitoring economic indicators like interest rates, growth, and liquidity can help investors anticipate market swings, not just rely on crypto-specific events.

Does this mean halvings no longer matter?

Halvings still influence Bitcoin by reducing new supply, but macroeconomic trends are now playing a larger role in shaping long-term price cycles.

DailyCoin's Vibe Check: Which way are you leaning towards after reading this article?

Market Sentiment

0% Neutral

This article is for information purposes only and should not be considered trading or investment advice. Nothing herein shall be construed as financial, legal, or tax advice. Trading forex, cryptocurrencies, and CFDs pose a considerable risk of loss.

A recent surge in gold and silver may be less the main event and more the opening act for a “meteoric” move in crypto.

Market Sentiment:

Bullish Bearish Neutral

Published: February 10, 2026 │ 3:55 PM GMT

Created by Gabor Kovacs from DailyCoin

An popular online market analyst is arguing that the recent surge in gold and silver is not the story in itself, but the opening move in a broader liquidity cycle that could eventually spill into Bitcoin, XRP, HBAR and other crypto assets.

Drawing heavily on comments from macro strategist Raoul Pal, Levi frames current price action in precious metals as a classic early signal that global financial conditions are easing and that risk assets may be next in line.

From “Everything Code Dominoes” To a Steady Utility-Based Crypto RotationThe video centers on what Pal calls the “everything code dominoes” — a sequence in which different asset classes respond, with lags, to changes in global financial conditions.

Sponsored

According to the discussion, gold, silver, and the dollar-yen pair are tightly linked to financial conditions and tend to move first, leading other assets by about nine months.

Bitcoin, the specialist says, lives “in liquidity land,” typically lagging those early signals by roughly three months.

Equities, particularly the Nasdaq, are described as tracking global liquidity “perfectly” in this framework. In the pandemic shock of 2020, gold rallied first, the host notes, before capital rotated into Bitcoin, which went on to dramatically outperform.

“Gold can do a couple hundred percent,” Pal is quoted as saying, “crypto can do five, ten X if you’re lucky.”

That historical relationship underpins the host’s argument that the current move in precious metals is setting the stage for crypto’s “time” again, once the liquidity phase is further along.

Central Banks, Weakened Dollar & Why XRP & HBAR Are Kept Under PressureLevi also stresses that major central banks are “loading up massively” on gold and, to a lesser extent, silver, while largely avoiding cryptocurrencies for now because of the perceived risk environment.

This is portrayed less as an anti-crypto stance and more as a function of their mandate: protecting sovereign wealth as the dollar weakens and debt burdens grow.

Pal notes that around 87% of world trade and over half of global debt are denominated in U.S. dollars, making the currency systemically unavoidable even as some sovereign wealth funds diversify.

In his view, a cyclical weakening of the dollar pushes these institutions into gold as a hedge, and increasingly, on the margin, into Bitcoin as well.

Against that backdrop, the host characterizes recent downside in Bitcoin, XRP, HBAR and other tokens as “short-term negative downside pressure” within a larger liquidity story.

Levi argues that “they want you out of XRP and HBAR right now so they can make more money when the liquidity is ready to come in,” suggesting institutional players prefer to accumulate during periods of retail capitulation.

While Levi acknowledges that gold now looks “wildly overbought” and that he would not initiate new positions at these levels, he and Pal both see room for the move to extend over “another two or three months” as financial conditions continue to ease.

In that scenario, crypto would be expected to follow later in the cycle, assuming no major structural shock intervenes.

For crypto investors, the message is less about short-term timing and more about understanding the sequence: central bank gold buying and a softer dollar as early indicators, followed by improving liquidity conditions, then eventual spillover into higher-beta assets such as Bitcoin and large-cap altcoins like XRP and HBAR.

Discover DailyCoin’s hottest crypto news right now:
Shiba Inu Hits Zero Coin Burns: What’s Going On Here?
Coinbase’s Karaoke Ad Bombs Super Bowl As Boos Erupt

People Also Ask:How long is the lag between gold and Bitcoin, according to the video?

The discussion cites roughly a nine-month lead from gold (and financial conditions) to Bitcoin, with global liquidity itself leading Bitcoin by about three months.

Why are central banks buying gold instead of crypto?

The video frames gold buying as a traditional way for central banks and sovereign wealth funds to hedge currency and debt risks. Crypto is seen as higher risk, with some interest emerging only at the margin, particularly in Bitcoin.

Does the analyst expect the U.S. dollar to disappear?

No. Pal emphasizes that the dollar is deeply embedded in trade and debt markets, so it is not “going away,” even if some countries diversify partially into gold and, over time, digital assets.

What is the outlook for XRP and HBAR in this framework?

The host suggests current weakness is temporary and tied to the broader risk-off phase, arguing that both could benefit once liquidity rotates into crypto later in the cycle, though no specific price targets are given.

DailyCoin's Vibe Check: Which way are you leaning towards after reading this article?

Market Sentiment

100% Bullish

This article is for information purposes only and should not be considered trading or investment advice. Nothing herein shall be construed as financial, legal, or tax advice. Trading forex, cryptocurrencies, and CFDs pose a considerable risk of loss.

Rigetti Computing, Inc. (RGTI - Free Report) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of the stock.

Over the past month, shares of this company have returned -31.1%, compared to the Zacks S&P 500 composite's no change. During this period, the Zacks Internet - Software industry, which Rigetti Computing falls in, has lost 7.2%. The key question now is: What could be the stock's future direction?

Although media reports or rumors about a significant change in a company's business prospects usually cause its stock to trend and lead to an immediate price change, there are always certain fundamental factors that ultimately drive the buy-and-hold decision.

Revisions to Earnings EstimatesRather than focusing on anything else, we at Zacks prioritize evaluating the change in a company's earnings projection. This is because we believe the fair value for its stock is determined by the present value of its future stream of earnings.

Our analysis is essentially based on how sell-side analysts covering the stock are revising their earnings estimates to take the latest business trends into account. When earnings estimates for a company go up, the fair value for its stock goes up as well. And when a stock's fair value is higher than its current market price, investors tend to buy the stock, resulting in its price moving upward. Because of this, empirical studies indicate a strong correlation between trends in earnings estimate revisions and short-term stock price movements.

For the current quarter, Rigetti Computing is expected to post a loss of $0.05 per share, indicating a change of +37.5% from the year-ago quarter. The Zacks Consensus Estimate remained unchanged over the last 30 days.

For the current fiscal year, the consensus earnings estimate of -$0.68 points to a change of -88.9% from the prior year. Over the last 30 days, this estimate has remained unchanged.

For the next fiscal year, the consensus earnings estimate of $0.18 indicates a change of +74.3% from what Rigetti Computing is expected to report a year ago. Over the past month, the estimate has remained unchanged.

Having a strong externally audited track record, our proprietary stock rating tool, the Zacks Rank, offers a more conclusive picture of a stock's price direction in the near term, since it effectively harnesses the power of earnings estimate revisions. Due to the size of the recent change in the consensus estimate, along with three other factors related to earnings estimates, Rigetti Computing is rated Zacks Rank #3 (Hold).

The chart below shows the evolution of the company's forward 12-month consensus EPS estimate:

12 Month EPS

Projected Revenue GrowthWhile earnings growth is arguably the most superior indicator of a company's financial health, nothing happens as such if a business isn't able to grow its revenues. After all, it's nearly impossible for a company to increase its earnings for an extended period without increasing its revenues. So, it's important to know a company's potential revenue growth.

For Rigetti Computing, the consensus sales estimate for the current quarter of $2.67 million indicates a year-over-year change of +17.7%. For the current and next fiscal years, $7.89 million and $26.41 million estimates indicate -26.9% and +234.7% changes, respectively.

Last Reported Results and Surprise HistoryRigetti Computing reported revenues of $1.95 million in the last reported quarter, representing a year-over-year change of -18.1%. EPS of -$0.03 for the same period compares with -$0.08 a year ago.

Compared to the Zacks Consensus Estimate of $2.39 million, the reported revenues represent a surprise of -18.54%. The EPS surprise was +40%.

Over the last four quarters, Rigetti Computing surpassed consensus EPS estimates two times. The company topped consensus revenue estimates times over this period.

ValuationWithout considering a stock's valuation, no investment decision can be efficient. In predicting a stock's future price performance, it's crucial to determine whether its current price correctly reflects the intrinsic value of the underlying business and the company's growth prospects.

While comparing the current values of a company's valuation multiples, such as price-to-earnings (P/E), price-to-sales (P/S), and price-to-cash flow (P/CF), with its own historical values helps determine whether its stock is fairly valued, overvalued, or undervalued, comparing the company relative to its peers on these parameters gives a good sense of the reasonability of the stock's price.

As part of the Zacks Style Scores system, the Zacks Value Style Score (which evaluates both traditional and unconventional valuation metrics) organizes stocks into five groups ranging from A to F (A is better than B; B is better than C; and so on), making it helpful in identifying whether a stock is overvalued, rightly valued, or temporarily undervalued.

Rigetti Computing is graded F on this front, indicating that it is trading at a premium to its peers. Click here to see the values of some of the valuation metrics that have driven this grade.

Bottom LineThe facts discussed here and much other information on Zacks.com might help determine whether or not it's worthwhile paying attention to the market buzz about Rigetti Computing. However, its Zacks Rank #3 does suggest that it may perform in line with the broader market in the near term.

Dallas, Texas--(Newsfile Corp. - February 10, 2026) - AB Science S.A. (ENXTPA: AB): Stonegate Capital Partners Initiates Coverage on AB Science S.A. (ENXTPA: AB). AB Science is a late-stage biotech advancing masitinib, an oral, selective tyrosine kinase inhibitor designed to modulate maladaptive neuroinflammation through mast-cell and microglia/macrophage pathways. The Company is positioning masitinib as an add-on therapy across ALS, progressive MS, and AD, while maintaining earlier-stage upside through AB8939 in AML. The combination of a treatment for ALS along with the optionality that comes with the rest of the Company's portfolio makes us excited to monitor the development of AB's Masitinib asset.

To view the full announcement, including downloadable images, bios, and more, click here.

Key Takeaways:

ALS program supported by prior Phase 2b/3 data For progressive MS, the Phase 3 trial is authorizedin the US and 12 EU countries with ~94 sites initiating Financing supported by grants

Click image above to view full announcement.

About Stonegate
Stonegate Capital Partners is a leading capital markets advisory firm providing investor relations, equity research, and institutional investor outreach services for public companies. Our affiliate, Stonegate Capital Markets (member FINRA) provides a full spectrum of investment banking services for public and private companies.

Source: Stonegate, Inc.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/283417

Source: Reportable, Inc.

Nice (NICE - Free Report) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of the key factors that could influence the stock's performance in the near future.

Shares of this software company have returned -4.5% over the past month versus the Zacks S&P 500 composite's no change. The Zacks Internet - Software industry, to which Nice belongs, has lost 7.2% over this period. Now the key question is: Where could the stock be headed in the near term?

Although media reports or rumors about a significant change in a company's business prospects usually cause its stock to trend and lead to an immediate price change, there are always certain fundamental factors that ultimately drive the buy-and-hold decision.

Earnings Estimate RevisionsRather than focusing on anything else, we at Zacks prioritize evaluating the change in a company's earnings projection. This is because we believe the fair value for its stock is determined by the present value of its future stream of earnings.

We essentially look at how sell-side analysts covering the stock are revising their earnings estimates to reflect the impact of the latest business trends. And if earnings estimates go up for a company, the fair value for its stock goes up. A higher fair value than the current market price drives investors' interest in buying the stock, leading to its price moving higher. This is why empirical research shows a strong correlation between trends in earnings estimate revisions and near-term stock price movements.

Nice is expected to post earnings of $3.23 per share for the current quarter, representing a year-over-year change of +7%. Over the last 30 days, the Zacks Consensus Estimate remained unchanged.

For the current fiscal year, the consensus earnings estimate of $12.28 points to a change of +10.4% from the prior year. Over the last 30 days, this estimate has remained unchanged.

For the next fiscal year, the consensus earnings estimate of $11.62 indicates a change of -5.4% from what Nice is expected to report a year ago. Over the past month, the estimate has remained unchanged.

With an impressive externally audited track record, our proprietary stock rating tool -- the Zacks Rank -- is a more conclusive indicator of a stock's near-term price performance, as it effectively harnesses the power of earnings estimate revisions. The size of the recent change in the consensus estimate, along with three other factors related to earnings estimates, has resulted in a Zacks Rank #4 (Sell) for Nice.

The chart below shows the evolution of the company's forward 12-month consensus EPS estimate:

12 Month EPS

Projected Revenue GrowthWhile earnings growth is arguably the most superior indicator of a company's financial health, nothing happens as such if a business isn't able to grow its revenues. After all, it's nearly impossible for a company to increase its earnings for an extended period without increasing its revenues. So, it's important to know a company's potential revenue growth.

In the case of Nice, the consensus sales estimate of $778.66 million for the current quarter points to a year-over-year change of +7.9%. The $2.94 billion and $3.18 billion estimates for the current and next fiscal years indicate changes of +7.4% and +8.2%, respectively.

Last Reported Results and Surprise HistoryNice reported revenues of $732 million in the last reported quarter, representing a year-over-year change of +6.1%. EPS of $3.18 for the same period compares with $2.88 a year ago.

Compared to the Zacks Consensus Estimate of $727.92 million, the reported revenues represent a surprise of +0.56%. The EPS surprise was +0.32%.

The company beat consensus EPS estimates in each of the trailing four quarters. The company topped consensus revenue estimates each time over this period.

ValuationNo investment decision can be efficient without considering a stock's valuation. Whether a stock's current price rightly reflects the intrinsic value of the underlying business and the company's growth prospects is an essential determinant of its future price performance.

While comparing the current values of a company's valuation multiples, such as price-to-earnings (P/E), price-to-sales (P/S), and price-to-cash flow (P/CF), with its own historical values helps determine whether its stock is fairly valued, overvalued, or undervalued, comparing the company relative to its peers on these parameters gives a good sense of the reasonability of the stock's price.

As part of the Zacks Style Scores system, the Zacks Value Style Score (which evaluates both traditional and unconventional valuation metrics) organizes stocks into five groups ranging from A to F (A is better than B; B is better than C; and so on), making it helpful in identifying whether a stock is overvalued, rightly valued, or temporarily undervalued.

Nice is graded B on this front, indicating that it is trading at a discount to its peers. Click here to see the values of some of the valuation metrics that have driven this grade.

ConclusionThe facts discussed here and much other information on Zacks.com might help determine whether or not it's worthwhile paying attention to the market buzz about Nice. However, its Zacks Rank #4 does suggest that it may underperform the broader market in the near term.

Marathon Petroleum (MPC - Free Report) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the facts that could shape the stock's performance in the near term.

Shares of this refiner have returned +16.4% over the past month versus the Zacks S&P 500 composite's no change. The Zacks Oil and Gas - Refining and Marketing industry, to which Marathon Petroleum belongs, has gained 14.7% over this period. Now the key question is: Where could the stock be headed in the near term?

Although media reports or rumors about a significant change in a company's business prospects usually cause its stock to trend and lead to an immediate price change, there are always certain fundamental factors that ultimately drive the buy-and-hold decision.

Revisions to Earnings EstimatesRather than focusing on anything else, we at Zacks prioritize evaluating the change in a company's earnings projection. This is because we believe the fair value for its stock is determined by the present value of its future stream of earnings.

Our analysis is essentially based on how sell-side analysts covering the stock are revising their earnings estimates to take the latest business trends into account. When earnings estimates for a company go up, the fair value for its stock goes up as well. And when a stock's fair value is higher than its current market price, investors tend to buy the stock, resulting in its price moving upward. Because of this, empirical studies indicate a strong correlation between trends in earnings estimate revisions and short-term stock price movements.

Marathon Petroleum is expected to post earnings of $0.98 per share for the current quarter, representing a year-over-year change of +508.3%. Over the last 30 days, the Zacks Consensus Estimate has changed -48.3%.

For the current fiscal year, the consensus earnings estimate of $12.74 points to a change of +19.1% from the prior year. Over the last 30 days, this estimate has changed -9.9%.

For the next fiscal year, the consensus earnings estimate of $13.98 indicates a change of +9.7% from what Marathon Petroleum is expected to report a year ago. Over the past month, the estimate has changed +3.6%.

Having a strong externally audited track record, our proprietary stock rating tool, the Zacks Rank, offers a more conclusive picture of a stock's price direction in the near term, since it effectively harnesses the power of earnings estimate revisions. Due to the size of the recent change in the consensus estimate, along with three other factors related to earnings estimates, Marathon Petroleum is rated Zacks Rank #3 (Hold).

The chart below shows the evolution of the company's forward 12-month consensus EPS estimate:

12 Month EPS

Projected Revenue GrowthEven though a company's earnings growth is arguably the best indicator of its financial health, nothing much happens if it cannot raise its revenues. It's almost impossible for a company to grow its earnings without growing its revenue for long periods. Therefore, knowing a company's potential revenue growth is crucial.

In the case of Marathon Petroleum, the consensus sales estimate of $28.93 billion for the current quarter points to a year-over-year change of -9.2%. The $120.94 billion and $119.88 billion estimates for the current and next fiscal years indicate changes of -10.6% and -0.9%, respectively.

Last Reported Results and Surprise HistoryMarathon Petroleum reported revenues of $33.42 billion in the last reported quarter, representing a year-over-year change of -0.1%. EPS of $4.07 for the same period compares with $0.77 a year ago.

Compared to the Zacks Consensus Estimate of $29.61 billion, the reported revenues represent a surprise of +12.89%. The EPS surprise was +49.08%.

Over the last four quarters, Marathon Petroleum surpassed consensus EPS estimates three times. The company topped consensus revenue estimates each time over this period.

ValuationWithout considering a stock's valuation, no investment decision can be efficient. In predicting a stock's future price performance, it's crucial to determine whether its current price correctly reflects the intrinsic value of the underlying business and the company's growth prospects.

While comparing the current values of a company's valuation multiples, such as price-to-earnings (P/E), price-to-sales (P/S), and price-to-cash flow (P/CF), with its own historical values helps determine whether its stock is fairly valued, overvalued, or undervalued, comparing the company relative to its peers on these parameters gives a good sense of the reasonability of the stock's price.

As part of the Zacks Style Scores system, the Zacks Value Style Score (which evaluates both traditional and unconventional valuation metrics) organizes stocks into five groups ranging from A to F (A is better than B; B is better than C; and so on), making it helpful in identifying whether a stock is overvalued, rightly valued, or temporarily undervalued.

Marathon Petroleum is graded B on this front, indicating that it is trading at a discount to its peers. Click here to see the values of some of the valuation metrics that have driven this grade.

Bottom LineThe facts discussed here and much other information on Zacks.com might help determine whether or not it's worthwhile paying attention to the market buzz about Marathon Petroleum. However, its Zacks Rank #3 does suggest that it may perform in line with the broader market in the near term.

Occidental Petroleum (OXY - Free Report) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of the key factors that could influence the stock's performance in the near future.

Over the past month, shares of this oil and gas exploration and production company have returned +9.2%, compared to the Zacks S&P 500 composite's no change. During this period, the Zacks Oil and Gas - Integrated - United States industry, which Occidental falls in, has gained 11.1%. The key question now is: What could be the stock's future direction?

Although media reports or rumors about a significant change in a company's business prospects usually cause its stock to trend and lead to an immediate price change, there are always certain fundamental factors that ultimately drive the buy-and-hold decision.

Revisions to Earnings EstimatesRather than focusing on anything else, we at Zacks prioritize evaluating the change in a company's earnings projection. This is because we believe the fair value for its stock is determined by the present value of its future stream of earnings.

Our analysis is essentially based on how sell-side analysts covering the stock are revising their earnings estimates to take the latest business trends into account. When earnings estimates for a company go up, the fair value for its stock goes up as well. And when a stock's fair value is higher than its current market price, investors tend to buy the stock, resulting in its price moving upward. Because of this, empirical studies indicate a strong correlation between trends in earnings estimate revisions and short-term stock price movements.

For the current quarter, Occidental is expected to post earnings of $0.19 per share, indicating a change of -76.3% from the year-ago quarter. The Zacks Consensus Estimate has changed -42.2% over the last 30 days.

The consensus earnings estimate of $2.11 for the current fiscal year indicates a year-over-year change of -39%. This estimate has changed -44.8% over the last 30 days.

For the next fiscal year, the consensus earnings estimate of $0.65 indicates a change of -69.1% from what Occidental is expected to report a year ago. Over the past month, the estimate has changed -44.9%.

With an impressive externally audited track record, our proprietary stock rating tool -- the Zacks Rank -- is a more conclusive indicator of a stock's near-term price performance, as it effectively harnesses the power of earnings estimate revisions. The size of the recent change in the consensus estimate, along with three other factors related to earnings estimates, has resulted in a Zacks Rank #4 (Sell) for Occidental.

The chart below shows the evolution of the company's forward 12-month consensus EPS estimate:

12 Month EPS

Revenue Growth ForecastWhile earnings growth is arguably the most superior indicator of a company's financial health, nothing happens as such if a business isn't able to grow its revenues. After all, it's nearly impossible for a company to increase its earnings for an extended period without increasing its revenues. So, it's important to know a company's potential revenue growth.

In the case of Occidental, the consensus sales estimate of $5.88 billion for the current quarter points to a year-over-year change of -14%. The $25.96 billion and $20.58 billion estimates for the current and next fiscal years indicate changes of -3.4% and -20.7%, respectively.

Last Reported Results and Surprise HistoryOccidental reported revenues of $6.72 billion in the last reported quarter, representing a year-over-year change of -6.1%. EPS of $0.64 for the same period compares with $1 a year ago.

Compared to the Zacks Consensus Estimate of $6.72 billion, the reported revenues represent a surprise of -0.07%. The EPS surprise was +33.33%.

The company beat consensus EPS estimates in each of the trailing four quarters. The company topped consensus revenue estimates times over this period.

ValuationWithout considering a stock's valuation, no investment decision can be efficient. In predicting a stock's future price performance, it's crucial to determine whether its current price correctly reflects the intrinsic value of the underlying business and the company's growth prospects.

While comparing the current values of a company's valuation multiples, such as price-to-earnings (P/E), price-to-sales (P/S), and price-to-cash flow (P/CF), with its own historical values helps determine whether its stock is fairly valued, overvalued, or undervalued, comparing the company relative to its peers on these parameters gives a good sense of the reasonability of the stock's price.

As part of the Zacks Style Scores system, the Zacks Value Style Score (which evaluates both traditional and unconventional valuation metrics) organizes stocks into five groups ranging from A to F (A is better than B; B is better than C; and so on), making it helpful in identifying whether a stock is overvalued, rightly valued, or temporarily undervalued.

Occidental is graded B on this front, indicating that it is trading at a discount to its peers. Click here to see the values of some of the valuation metrics that have driven this grade.

ConclusionThe facts discussed here and much other information on Zacks.com might help determine whether or not it's worthwhile paying attention to the market buzz about Occidental. However, its Zacks Rank #4 does suggest that it may underperform the broader market in the near term.

Here are three stocks with buy rank and strong value characteristics for investors to consider today, February 10th:  

Patria Investments Limited (PAX - Free Report) : This private market investment firms principally in Latin America, which offers asset management services to investors focusing on private equity funds, infrastructure development funds, co-investments funds, constructivist equity funds and real estate and credit funds, carries a Zacks Rank #1 (Strong Buy), and has witnessed the Zacks Consensus Estimate for its current year earnings increasing 4% over the last 60 days.

Patria Investments Limited's has a price-to-earnings ratio (P/E) of 9.16 compared with 23.80 for the industry. The company possesses a Value Score of A.

Tokio Marine (TKOMY - Free Report) : This Japan-based holding company, which is engaged in the non-life insurance, life insurance and asset management businesses, carries a Zacks Rank #1, and has witnessed the Zacks Consensus Estimate for its current year earnings increasing 3.5% over the last 60 days.

Tokio Marine has a price-to-earnings ratio (P/E) of 10.40 compared with 12.80 for the industry. The company possesses a Value Score of A.

Popular (BPOP - Free Report) : This full-service financial services provider, which has operations in Puerto Rico, the U.S. mainland and the U.S. and British Virgin Islands, carries a Zacks Rank #1, and has witnessed the Zacks Consensus Estimate for its current year earnings increasing 4.1% over the last 60 days.

Popular’s has a price-to-earnings ratio (P/E) of 10.29 compared with 11.70 for the industry. The company possesses a Value Score of B.

See the full list of top ranked stocks here.

Learn more about the Value score and how it is calculated here.

Key Takeaways The Consumer Staples sector is up 13.2% YTD, ranking third among S&P 500 broad sectors amid a value rotation.EL, HSY, KMB, MNST and NYT are cited as top consumer staples picks to tap sector's ongoing momentum.The group is benefiting from pricing discipline, innovation, digital expansion and supply-chain improvements. Wall Street’s impressive bull run of the last three years has received an initial breakthrough this year, too. The consumer staples sector, which has not participated in this astonishing growth of U.S. stock markets so far, has gathered momentum. 

As market participants shifted their preference from highly overvalued growth-oriented sectors to more value-oriented sectors, consumer staples stocks gathered pace. Year to date, the Consumer Staples Select Sector SPDR (XLP), one out of the 11 broad sectors of the S&P 500 Index, has advanced 13.2%, third only after the Energy and Materials sectors.

At this stage, we recommend buying five consumer staples behemoths with a favorable Zacks Rank. These are: The Estée Lauder Companies Inc. (EL - Free Report) , The Hershey Co. (HSY - Free Report) , Kimberly-Clark Corp. (KMB - Free Report) , Monster Beverage Corp. (MNST - Free Report) and The New York Times Co. (NYT - Free Report) . Each of our picks currently carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here. 

The chart below shows the price performance of our five picks year to date.

Image Source: Zacks Investment Research

The Estée Lauder Companies Inc.Estée Lauder is focused on rebuilding profitability through its expanded Profit Recovery and Growth Plan, which aims to restore margins while supporting sustainable sales growth. EL’s disciplined cost actions combined with increased consumer-facing investments are improving efficiency and agility. 

The “Beauty Reimagined” strategy of EL is gaining traction through stronger innovation, expanded global reach and improved brand execution. Digital remains a key growth driver, supported by social commerce, broader online distribution and a new Shopify partnership. Solid momentum in emerging markets, including China, Mexico and India, further supports confidence in a durable turnaround and long-term growth.

Estée Lauder has an expected revenue and earnings growth rate of 4% and 46.4%, respectively, for the current year (ending June 2026). The Zacks Consensus Estimate for the current year’s earnings has improved 1.8% over the last seven days. EL has a current dividend yield of 1.41%.

The Hershey Co.Hershey is focused on strengthening innovation, supply-chain agility and commercial execution as it expands its presence across the snacking category. HSY is supported by strong pricing discipline, a successful innovation pipeline and solid growth in salty snacks. 

Hershey is progressing through a multi-year transformation that modernizes and integrates its supply chain, strengthens commercial capabilities, and enhances demand forecasting and execution. HSY highlighted upgrades across procurement, production, distribution and commercial planning, supported by investments in data, analytics and digital tools.

HSY’s retail takeaway improved across core categories, reflecting better shelf execution and effective brand investment. Management expressed confidence in returning to its long-term growth algorithm in the following year.

Hershey has an expected revenue and earnings growth rate of 4.1% and 13.3%, respectively, for the current year. The Zacks Consensus Estimate for the current year’s earnings has improved 2% over the last seven days. HSY has a current dividend yield of 2.37%.

Kimberly-Clark Corp.Kimberly-Clark is advancing its transformation through the Powering Care strategy, with fourth-quarter 2025 results showing improving growth quality, profitability and organizational focus. Innovation remains a central pillar of KMB’s growth agenda, with management underscoring that recent performance has become increasingly innovation-led across its portfolio.

KMB’s stronger organic growth and volume trends reflect better consumer engagement and more consistent execution across regions. Innovation-led performance, guided by a structured “good-better-best” approach, is driving premiumization, expanding consumer reach and reinforcing brand strength. 

The shift toward a volume and mix-led growth model underscores healthier demand dynamics, while solid productivity execution and supply-chain efficiencies help protect KMB’s margins and support continued reinvestment.

Hershey has an expected revenue and earnings growth rate of -2.1% and -6.2%, respectively, for the current year. The Zacks Consensus Estimate for the current year’s earnings has improved 0.2% over the last 30 days. KMB has a current dividend yield of 4.83%.

Monster Beverage Corp.Monster Beverage continues to benefit from the expansion of the energy drinks market and product launches, reinforcing its category strength. MNST continues to benefit from constant growth in the global energy drink market, backed by strong demand across convenience stores and other key retail channels. Improving margins, supported by easing supply-chain pressures and lower costs, have contributed to MNST’s financial stability.

Product innovation remains a core growth driver for MNST. The company continues to invest heavily in new launches to strengthen its global footprint. Last year, Monster Beverage rolled out several high-profile innovations, with a solid innovation pipeline planned for 2026. 

Building on the success of its $1 billion Ultra brand, MNST also introduced a new visual identity and merchandising strategy with dedicated Zero Sugar coolers, supported by a viral social media campaign around its flagship Zero Ultra drink.

Monster Beverage has an expected revenue and earnings growth rate of 9.5% and 22.8%, respectively, for the current year. The Zacks Consensus Estimate for the current year’s earnings has improved 0.5% over the last 60 days. 

The New York Times Co.New York Times is capitalizing on its multi-platform strategy to drive digital growth, broaden audience engagement, and diversify revenue streams. NYT’s expansion into lifestyle categories such as Cooking, Games, and Sports, supported by bundled subscription offerings, is deepening customer relationships and boosting retention. 

Strong execution in digital subscription growth and ARPU improvement reflects effective monetization of NYT’s content portfolio. A solid balance sheet and healthy free cash flow provide ample flexibility for continued investment and shareholder returns. While the ongoing decline in print and rising operating costs pose structural challenges, NYT’s ability to adapt quickly and leverage high-value verticals positions it well for growth.

New York Times has an expected revenue and earnings growth rate of 7.9 and 11.8%, respectively, for the current year. The Zacks Consensus Estimate for the current year’s earnings has improved 2.2% over the last seven days. NYT has a current dividend yield of 1.06%.

Q4: 2026-02-10 Earnings SummaryEPS of $0.71 beats by $0.21

 |

Revenue of

$6.07B

(15.37% Y/Y)

beats by $234.60M

Koninklijke Philips N.V. (PHG) Q4 2025 Earnings Call February 10, 2026 3:00 AM EST

Company Participants

Durga Doraisamy - Head of Investor Relations
Roy Jakobs - President, CEO & Chairman of the Board of Management
Charlotte Hanneman - Executive VP, CFO & Member of Board of Management

Conference Call Participants

Hassan Al-Wakeel - Barclays Bank PLC, Research Division
Richard Felton - Goldman Sachs Group, Inc., Research Division
Julien Dormois - Jefferies LLC, Research Division
Veronika Dubajova - Citigroup Inc., Research Division
Hugo Solvet - BNP Paribas, Research Division

Presentation

Operator

Welcome to the Philips' Fourth Quarter and Full Year 2025 Results Conference Call on Tuesday, February 10, 2026. During the call hosted by Mr. Roy Jakobs, CEO; and Ms. Charlotte Hanneman, CFO, all participants will be in a listen-only mode. [Operator Instructions]. Please note that this call will be recorded, and the replay will be available on the Investor Relations website of Royal Philips.

I will now hand the conference over to Ms. Durga Doraisamy, Head of Investor Relations. Please go ahead, madam.

Durga Doraisamy
Head of Investor Relations

Thank you. Good morning from London, everyone. Today, we will start by reviewing our fourth quarter and full year 2025 results, followed by a short Q&A session. Then at 11 a.m., our Capital Markets Day webcast will begin and run until 4:00 p.m. You will hear from Roy, Charlotte and our Chief Business Leaders as they share how we're driving profitable growth to deliver sustainable value. The program continues with a North America-based Philips customer panel, providing real-world customer insights. Roy will wrap up the day with closing remarks and key takeaways.

The press release for both events was published on our website this morning. The replay and full-time script of the webcast along with the presentation and transcript for our Capital Markets Day will be

Philadelphia, Pennsylvania--(Newsfile Corp. - February 10, 2026) - National plaintiffs' law firm Berger Montague PC announces that a class action lawsuit has been filed against Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) ("Ultragenyx" or the "Company") on behalf of investors who purchased Ultragenyx common stock during the period from August 3, 2023 through December 26, 2025 (the "Class Period").

Investor Deadline: Investors who purchased Ultragenyx securities during the Class Period may, no later than April 6, 2026, seek to be appointed as a lead plaintiff representative of the class. To learn your rights, CLICK HERE.

Headquartered in Novato, Calif., Ultragenyx is a biopharmaceutical company specializing in treatments for rare diseases.

According to the complaint, while publicly raising investor expectations about the ORBIT and COSMIC studies, which tested setrusumab as a treatment for Osteogenesis Imperfecta, Defendants misled investors by concealing that neither study significantly reduced the clinical fracture rates compared to control groups. Following the disclosure, Ultragenyx's share price plummeted from a close of $34.19 on December 26, 2025 to a close of $19.72 per share on December 29, erasing more than 42% of its value in a single day.

If you are a Ultragenyx investor and would like to learn more about this action, CLICK HERE or please contact Berger Montague: Andrew Abramowitz at [email protected] or (215) 875-3015, or Caitlin Adorni at [email protected] or (267)764-4865.

About Berger Montague
Berger Montague is one of the nation's preeminent law firms focusing on complex civil litigation, class actions, and mass torts in federal and state courts throughout the United States. With more than $2.4 billion in 2025 post-trial judgments alone, the Firm is a leader in the fields of complex litigation, antitrust, consumer protection, defective products, environmental law, employment law, securities, and whistleblower cases, among many other practice areas. For over 55 years, Berger Montague has played leading roles in precedent-setting cases and has recovered over $50 billion for its clients and the classes they have represented. Berger Montague is headquartered in Philadelphia and has offices in Chicago; Malvern, PA; Minneapolis; San Diego; San Francisco; Toronto, Canada; Washington, D.C., and Wilmington, DE.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/283209

Source: Berger Montague

Ready to Announce with Confidence? Send us a message and a member of our TMX Newsfile team will contact you to discuss your needs.

Contact Us

Key Takeaways DUK posted Q4 EPS of $1.50, missing estimates and falling 9.6% year over year despite revenue growth.Duke Energy's Q4 revenues rose 7.9% to $7.94B, beating estimates, while full-year sales reached $32.24B.Higher fuel, depreciation and interest costs pressured earnings, even as customers and sales volumes grew. Duke Energy Corporation's (DUK - Free Report) fourth-quarter 2025 earnings of $1.50 per share lagged the Zacks Consensus Estimate of $1.51 by 0.6%. The bottom line also declined 9.6% from $1.66 reported in the year-ago quarter.

For 2025, CMS reported adjusted earnings of $6.31 per share, higher than the prior-year figure of $5.90.

DUK’s Total RevenuesTotal operating revenues were $7.94 billion, which beat the Zacks Consensus Estimate of $7.66 billion by 3.9%. The top line also increased 7.9% from $7.36 billion in the year-ago period.

The company reported revenues of $32.24 billion in 2025, higher than $30.36 billion in 2024.

Highlights of DUK’s Earnings ReleaseTotal operating expenses amounted to $5.83 billion in the reported quarter, up 11% year over year. The increase was primarily driven by higher expenses for the cost of natural gas, operation, maintenance and other, depreciation and amortization, as well as property and other taxes.

The operating income totaled $2.119 billion compared with $2.112 billion in the year-ago quarter.

Interest expenses rose to $946 million from $871 million in the fourth quarter of 2024.

The average number of customers in its Electric Utilities increased 1.5% year over year.

Total electric sales volume for the reported quarter went up 2.3% year over year to 61,726 gigawatt-hours.

DUK’s Segmental HighlightsElectric Utilities & Infrastructure: This segment’s adjusted earnings for the fourth quarter totaled $1.21 billion, down from $1.24 billion in the fourth quarter of 2024. The decline was mainly due to higher O&M and depreciation on a growing asset base and interest expense, partially offset by the recovery of infrastructure investments.

Gas Utilities & Infrastructure: Adjusted earnings from this segment amounted to $230 million compared with $231 million in the fourth quarter of 2024.

Other: The segment includes corporate interest expenses not allocated to other business units, resulting from Duke Energy’s captive insurance company and other investments. This segment incurred a loss of $272 million compared with a loss of $186 million in the fourth quarter of 2024.

Financial Condition of DUKAs of Dec. 31, 2025, Duke Energy had cash & cash equivalents of $245 million compared with $314 million as of Dec. 31, 2024.

As of Dec. 31, 2025, the long-term debt was $80.11 billion compared with $76.34 billion as of Dec. 31, 2024.

The company generated net cash from operating activities of $12.330 billion in 2025 compared with $12.328 billion last year.

2026 Guidance by DUKDuke Energy expects to generate 2026 adjusted EPS in the range of $6.55-$6.80. The Zacks Consensus Estimate for 2025 earnings is pegged at $6.70, which is higher than the midpoint of the company’s projected range.

DUK extends its long-term EPS growth of 5-7% through 2030.

DUK’s Zacks RankUpcoming Utility ReleasesEdison International (EIX - Free Report) is scheduled to report fourth-quarter results on Feb. 18, after market close. The Zacks Consensus Estimate for earnings is pegged at $1.47 per share, which suggests a year-over-year increase of 40%.

EIX’s long-term (three to five years) earnings growth rate is 10.93%. The Zacks Consensus Estimate for fourth-quarter sales is pinned at $4.38 billion, which implies a year-over-year improvement of 9.9%.

Alliant Energy (LNT - Free Report) is slated to report fourth-quarter results on Feb. 19, after market close. The Zacks Consensus Estimate for earnings is pegged at 58 cents per share, which implies a year-over-year decrease of 17.1%.

LNT’s long-term earnings growth rate is 7.15%. The Zacks Consensus Estimate for fourth-quarter sales is pinned at $937.84 million, which implies a year-over-year decline of 3.9%.

AES Corporation (AES - Free Report) is slated to report fourth-quarter results on Feb. 26, after market close. The Zacks Consensus Estimate for earnings is pegged at 62 cents per share, which implies a year-over-year increase of 14.8%.

AES’ long-term earnings growth rate is 11.17%. The Zacks Consensus Estimate for fourth-quarter sales is pinned at $3.49 billion, which implies year-over-year growth of 17.8%.

Key Takeaways ORCL jumped nearly 10% on Feb. 9 after D.A. Davidson upgraded the stock to Buy with a $180 price target.The upgrade cites a correction after a 25% drop and stabilizing sentiment around ORCL's AI exposure. ETFs like IGV offer diversified exposure to ORCL while reducing single-stock risk. Following a week of general tech selloffs that caused a sector-wide loss of nearly $1 trillion, Oracle Corporation (ORCL - Free Report) emerged as a bright spot in the stock market. Its shares jumped nearly 10% on Feb. 9 after a D.A. Davidson analyst upgraded the stock to ‘Buy,’ reigniting investor interest in the software giant.

For those looking to capitalize on this momentum without the concentrated risk of a single stock, gaining exposure through Exchange-Traded Funds (ETFs) offers a diversified way to benefit from Oracle’s upward trajectory.

Before delving into the names and specifics of these ETFs, let us first examine what prompted the D.A. Davidson analyst to upgrade

ORCL and whether the stock truly offers upside potential. We also explain why ETF exposure, rather than direct stock ownership, is recommended. To support this view, we present the following analysis.

What Led to the Upgrade?Analyst Gil Luria of D.A. Davidson upgraded Oracle, maintaining a $180 price target, based on two core convictions:

1.    Market Overreaction Correcting: Luria believes the recent plunge in Oracle’s share price — down roughly 25% over eight sessions — was an overcorrection. He stated that the sentiment toward Oracle’s AI exposure was beginning to stabilize.

2.    OpenAI's Financial Strength as a Key Catalyst: Another key driver of the upgrade is the improved outlook for OpenAI, a major Oracle cloud customer. In this context, Luria estimated that OpenAI already has around $40 billion in cash and could raise another $100 billion in the near term (as cited in Trading View). This funding is critical to financing the data centers Oracle is building for the AI leader. Luria believes the fundraising will serve as a catalyst for the stock’s outperformance.

Can Oracle Sustain the Share Price Hike?As Oracle’s forward-looking strategy remains deeply rooted in the generative AI revolution, some analysts, including Luria, express a bullish view on the software giant’s future trajectory, largely based on excerpts from its most recent earnings call transcript:

•    Explosive Cloud Infrastructure Growth: Oracle Cloud Infrastructure (“OCI”) revenues grew 66% year over year in the fiscal second quarter, with GPU-related revenues skyrocketing 177%. The company reported handing over nearly 400 megawatts of data center capacity and delivering GPU capacity that is 50% higher than the prior quarter.

•    Massive and Diversified Backlog: Another factor supporting a bullish view on the stock is Oracle’s sizable remaining performance obligations (RPO) of $523.3 billion, which rose 433% year over year. This backlog, driven by high-capacity contracts with giants like Meta and NVIDIA, provides a highly visible and stable revenue runway that sets Oracle apart from its peers. 

Oracle’s story is complex, involving a planned $50 billion capital raise and significant debt, which could introduce volatility and limit the appeal of a single-stock investment, particularly at the current premium valuation. ORCL trades at a trailing 12-month earnings multiple of 27.57, slightly above the industry average of 27.4. Its long-term debt-to-equity ratio is 328.28, far higher than the sector average of 25.35.

On the same day, Luria upgraded Oracle, Melius Research downgraded the stock to Hold from Buy, citing its significant debt load and questioning its valuation given the expectation of no free cash flow until the 2030s (as cited in Yahoo Finance). This implies that not all analysts maintain a bullish stance on ORCL.

ETFs to Bet OnIn light of the discussion above, investors may look to the following ETFs with significant ORCL exposure to participate in Oracle’s AI opportunity while reducing company-specific financial and execution risks through diversification.

iShares Expanded Tech-Software Sector ETF (IGV - Free Report)

This fund, with net assets worth $7.37 billion, provides exposure to 114 software companies in the technology and communication services sectors. Of these, Oracle holds the fourth spot, with a 7.30% share of the fund.

This fund charges 39 basis points (bps) as fees. It traded at a good volume of 28.98 million shares in the last trading session. 

Pacer Data and Digital Revolution ETF (TRFK - Free Report)

This fund, with net assets worth $453 million, provides exposure to 87 data and digital revolution companies. Of these, Oracle holds the fifth spot, with a 7.20% share of the fund.

This fund charges 49 bps as fees. It traded at a good volume of 0.09 million shares in the last trading session. 

Janus Henderson Transformational Growth ETF (JXX - Free Report)

This fund, with net assets worth $33.6 million, provides exposure to 24 companies benefiting from durable trends transforming society, including AI, deglobalization, health care innovation, digitization and migration to the cloud. Of these, Oracle holds the fourth spot, with a 7.50% share of the fund.

This fund charges 57 bps as fees. It traded at a good volume of 0.02 million shares in the last trading session.

First Trust NASDAQ Technology Dividend ETF (TDIV - Free Report)

This fund, with net assets worth $3.80 billion, provides exposure to 93 technology and telecommunications companies that pay a regular or common dividend. Of these, Oracle holds the fifth spot, with a 5.04% share of the fund.

This fund charges 50 bps as fees. It traded at a good volume of 0.11 million shares in the last trading session. 

For investors seeking momentum, the THOR Equal Weight Low Volatility ETF (THLV - Free Report) is probably on the radar now. The fund just hit a 52-week high and is up 28.4% from its 52-week low price of $25.26 per share.  

But are there more gains in store for this ETF? Let’s take a quick look at the fund and its near-term outlook to get a better sense of where it might head.

THLV in FocusThe fund provides exposure to U.S. large-cap equities while attempting to lower volatility by avoiding sectors that are currently in a down-trending cycle. The fund charges 64 basis points (bps) in annual fees (See: all Style-Box Large-Cap Blend ETFs here).

What Led to the Rise?THLV has recently benefited from equal-weight allocations to materials and health care, sectors that outperform during periods of market volatility. Its systematic avoidance of risk-off sectors allows it to capture market upside while maintaining a low-volatility posture, pushing the fund toward a 52-week high.

More Gains Ahead?THLV may continue its strong performance in the near term, with a positive weighted alpha of 20.41 (as per Barchart.com), which suggests a further rally.

CVS Health Corp (NYSE:CVS) on Tuesday reported stronger-than-expected fourth-quarter revenue and adjusted earnings, driven by growth across its pharmacy, health services, and insurance businesses.

The US pharmacy chain and health insurer said fourth-quarter revenue rose 8.2% to $105.7 billion, topping analysts’ expectations of $103.6 billion.

Adjusted earnings per share (EPS) came in at $1.09, above the $1.00 forecast. GAAP net income for the quarter was $2.923 billion, with operating income of $2.112 billion.

Full-year 2025 revenue climbed 7.8% to a record $402.1 billion. Adjusted EPS for the year was $6.75, while GAAP diluted EPS was $1.39. The company generated $10.6 billion in cash flow from operations for the year.

Operationally, CVS said its pharmacy segment completed the transition to cost-based reimbursement across commercial, Medicare, and Medicaid businesses. Health insurer Aetna approved more than 95% of all eligible prior authorizations within 24 hours, with many processed instantaneously. CVS Caremark also reported strong customer retention and wins heading into 2026.

Looking ahead, CVS confirmed its 2026 full-year guidance for adjusted EPS at $7 to $7.20, slightly above analysts’ estimate of $7.17. GAAP EPS guidance is set at $5.94 to $6.14. The company updated its cash flow from operations guidance to at least $9 billion, down from the previous $10 billion.

“Our fourth quarter and full-year results demonstrate the progress we are making in transforming the health care experience with our unique collection of businesses,” CVS CEO David Joyner said. “From lowering drug prices, to improving navigation of health care, to being the front door of care across our country, we are well positioned to achieve our ambition to be the most trusted health care company in America.”

Shares rose 2.6% in early trading.

February 10, 2026 09:00 ET  | Source: Carlsmed

CARLSBAD, Calif., Feb. 10, 2026 (GLOBE NEWSWIRE) -- Carlsmed, Inc. (Nasdaq: CARL) (“Carlsmed” or the “Company”), today announced the successful completion of the first posterior lumbar spine surgery using the Company’s aprevo® Lumbar Bi-lateral Posterior System. The procedure was performed by Orthopedic Spine Surgeon CJ Kleck, M.D. at the University of Colorado Hospital in Denver, Colorado.

“This clinical milestone strengthens our position as a leader in personalized, data-driven spine solutions designed to help surgeons plan with greater precision, improve patient outcomes, and reduce costly revisions. The addition of the aprevo® Bi-lateral Posterior Lumbar Interbody Fusion procedure to our personalized surgery procedure portfolio further demonstrates the power and versatility of our personalized, AI-enabled approach to spine surgery,” said Mike Cordonnier, Chairman and CEO of Carlsmed. “We look forward to our full commercial launch this year to provide this personalized procedural option to patients, surgeons, and hospital systems on a larger scale.”

“Carlsmed’s aprevo® technology is integral to my pre-operative, intra-operative, and post-operative workflow, and extending its use across additional lumbar fusion approaches allows me to more precisely tailor treatment to each patient,” said Dr. Kleck. “Being able to personalize procedures based on each patient’s anatomy and pathology gives me greater confidence in achieving alignment goals. Adding a Bi-lateral posterior system to the list of procedures addressable with aprevo® will enable me to utilize this technology across a broader range of patients.”

Carlsmed’s Bi-lateral Posterior Fusion System integrates seamlessly with the Company’s broader aprevo® platform technology, which combines proprietary AI-enabled software and clinical intelligence to deliver personalized surgical strategies and preoperative planning across a range of spinal pathologies. The Company expects to commercially launch the system later this year.

About Carlsmed 
Carlsmed is a medical technology company pioneering AI-enabled personalized spine surgery solutions with a mission to improve outcomes and decrease the cost of healthcare for spine surgery and beyond.

Forward Looking Statements
Any statements in this press release about future expectations, plans and prospects, including statements about the timing of the commercial launch of the Company’s Bi-Lateral Posterior Fusion System, the potential of the Company’s products, the ability of the Company’s products to improve patient outcomes and reduce revision surgeries, and other statements containing the words “anticipate,” “believe,” “estimate,” “expect,” “intend,” “may,” “plan,” “predict,” “project,” “target,” “potential,” “likely,” “will,” “would,” “could,” “should,” “continue,” and similar expressions, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including such important factors as are set forth under the caption “Risk Factors” in Carlsmed’s Registration Statement on Form S-1 on file with the U.S. Securities and Exchange Commission. The forward-looking statements included in this press release represent Carlsmed’s views as of the date of this press release. Carlsmed anticipates that subsequent events and developments will cause its views to change. However, while Carlsmed may elect to update these forward-looking statements at some point in the future, it specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing Carlsmed’s views as of any date subsequent to the date of this press release.

Investor Relations 
Caroline Corner, PhD
[email protected] 

Media 
LeAnn Burton 
Senior Director Brand Marketing 
[email protected] 

The new partnership combines Weight Watchers’ scientifically-backed medical and behavioral expertise with PVOLVE’s clinically-studied method to support members at every age and stage of life February 10, 2026 09:00 ET  | Source: WW International Inc.

NEW YORK, Feb. 10, 2026 (GLOBE NEWSWIRE) -- WW International, Inc. (NASDAQ: WW) (“Weight Watchers”), the global leader in science-backed weight health, today announced a strategic partnership with PVOLVE, the clinically validated workout method, designed to support longevity through strength, mobility, and stability training.

As weight health enters a new era driven by GLP-1 medications and growing awareness of the role lean muscle plays in metabolism, Weight Watchers continues to innovate its science-backed approach to deliver even stronger outcomes for members. Building and preserving muscle plays an important role in long-term health, especially for women in midlife and members using GLP-1 medications.

To meet these evolving needs, Weight Watchers is further expanding its integrated approach by deepening its strength-forward movement offerings through PVOLVE’s clinically validated method to support members throughout their weight health journey and promote overall longevity.

Starting today, Weight Watchers members will gain access to exclusive PVOLVE classes suitable for all fitness levels and life stages through the WeightWatchers Core, Core+, Med+, GLP-1 Success and Menopause programs. Members will also be able to upgrade to PVOLVE’s full on-demand library through Weight Watchers and purchase a curated starter kit featuring PVOLVE’s best-selling unique resistance equipment.

For members using GLP-1 medications, strength training plays a critical role in supporting lean muscle and long-term success. The Weight Watchers Med+ Program, which includes their GLP-1 Success Program combines board-certified clinicians, behavioral science, personalized nutrition, strength-building plans, and expert coaching and community support to help manage side effects and deliver better outcomes than medication alone.

Data shows the positive impact of this integrated approach. At one month, regularly engaged Weight Watchers Med+ members lost 61.3% more body weight than those who took medicine alone; and at twelve months, 29.1% more.

Women lose 3-5% of muscle mass per decade, starting at age 30, but PVOLVE’s workouts have been shown to help partially offset this decline. In a 12-week PVOLVE program, participants experienced significant increases in lean muscle mass and improved lower body strength by 19%.

By pairing Weight Watchers’ holistic approach to nutrition, behavior change support, and medical care with PVOLVE’s fitness method, members receive a more personalized and comprehensive approach to weight health.

"As the definition of weight health evolves, so does our approach,” said Julie Rice, Chief Experience Officer of Weight Watchers. “This partnership with PVOLVE builds on our foundation by bringing more strength-forward movement into our ecosystem alongside nutrition, behavior change, coaching, and medical care - so our members can achieve more sustainable, long-term results."

“Movement should empower you, not exhaust you,” said Rachel Katzman, Founder of PVOLVE. “PVOLVE was created to help people feel strong, capable, and confident in their bodies through every stage of life, and we saw a natural partnership with Weight Watchers in that shared vision. For more than six decades, they’ve supported millions of people with a science-backed, comprehensive approach to health, and together we’re bringing movement, nutrition, medical care and coaching together in a way that truly supports real, lasting change and longevity.”

What Members Receive Through Weight Watchers + PVOLVE Partnership:
As part of the collaboration, all Weight Watchers members will gain access to exclusive benefits from PVOLVE, including:

Weight Watchers + PVOLVE Streaming Membership: Immediate access to select custom PVOLVE workouts through the Weight Watchers app – designed for all fitness levels and life stages, with specialized series for women in perimenopause and menopause, and a dedicated GLP-1 strength series.Expanded PVOLVE streaming experience: The opportunity to unlock the full PVOLVE library of 1,700+ on-demand classes through the Weight Watchers app at a special reduced member rate.Weight Watchers + PVOLVE Starter Kit: A curated kit featuring PVOLVE’s best-selling essentials, which include – Gliders, Floor Gloves, Heavy Ankle Band, P.ball, and P.band, also at a reduced member rate. As weight health solutions become increasingly fragmented, Weight Watchers is setting the industry standard by delivering a fully integrated experience that unites medical care, nutrition, behavior change, and movement in one connected platform. The partnership with PVOLVE builds on this foundation to further recognize strength, mobility, and muscle preservation as essential contributing pillars of lasting weight health.

ABOUT WEIGHT WATCHERS
Weight Watchers is the global leader in science-backed weight management, offering an integrated support system built for the GLP-1 era that combines scientific expertise, medication, cutting-edge technology, and human connection. With more than 60 years of experience, Weight Watchers is the most studied commercial weight management program in the world, delivered through its No. 1 U.S. doctor-recommended weight-loss program. Its holistic, personalized approach also includes U.S.-based clinical interventions and access to GLP-1 medications when clinically appropriate, and a global network of coaches and community support. Since 1963, the company has led with science to deliver its members the personalized support they need to reach and sustain their goals. Members can access these solutions directly, or through Weight Watchers for Business’ full-spectrum platform for employers, health plans, and payers. In a landscape crowded with contradictory advice, isolating apps, and one-size-fits-all solutions, Weight Watchers offers a proven path forward that is rooted in research, grounded in empathy and designed to help every member feel better in their body and live a longer, healthier life. For more information, visit weightwatchers.com.

ABOUT PVOLVE
PVOLVE is the first clinically-proven movement longevity company- built on a method that uniquely combines the three pillars of longevity training: strength, mobility, and stability. Using patented resistance equipment and functional movement patterns, PVOLVE sculpts and tones the body while helping members move better, longer. Founded by Rachel Katzman in 2017, the PVOLVE Method is backed by a Clinical Advisory Board of expert physicians and highly credentialed trainers with expertise in human physiology and biomechanics. In June 2023, world-renowned actress Jennifer Aniston officially partnered with PVOLVE after experiencing transformative results, calling the method “a game changer” for how she felt and looked. PVOLVE has a hybrid fitness model, offering more than 1,700 on-demand workouts, a two-way live virtual studio, and targeted series across web and mobile apps. The brand has over 30 studio locations open across North America, with more than 50 additional studios in development. Learn more at pvolve.com and pvolvefranchise.com.

For media inquiries, please contact:
Lizzy Levitan 
[email protected]

For investor inquiries, please contact:
John Mills or Anna Kate Heller
[email protected]

February 10, 2026 09:00 ET  | Source: MKS Inc.

ANDOVER, Mass., Feb. 10, 2026 (GLOBE NEWSWIRE) -- MKS Inc. (NASDAQ: MKSI), a global provider of enabling technologies that transform our world, today announced that its Board of Directors has authorized a quarterly cash dividend of $0.25 per share, an increase of 14% from its Q4 2025 dividend, payable on March 6, 2026, to shareholders of record as of February 23, 2026.

Future dividend declarations, as well as the record and payment dates for such dividends, are subject to the final determination of the Company's Board of Directors.

About MKS Inc.
MKS Inc. (NASDAQ: MKSI) enables technologies that transform our world. We deliver foundational technology solutions to leading edge semiconductor manufacturing, electronics and packaging, and specialty industrial applications. We apply our broad science and engineering capabilities to create instruments, subsystems, systems, process control solutions and specialty chemicals technology that improve process performance, optimize productivity and enable unique innovations for many of the world’s leading technology and industrial companies. Our solutions are critical to addressing the challenges of miniaturization and complexity in advanced device manufacturing by enabling increased power, speed, feature enhancement, and optimized connectivity. Our solutions are also critical to addressing ever-increasing performance requirements across a wide array of specialty industrial applications. Additional information can be found at www.mks.com.

Safe Harbor for Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 regarding MKS’ dividend program and any future dividend payment obligations. Any statements that are not statements of historical fact should be considered to be forward-looking statements. Actual events or results may differ materially from those in the forward-looking statements set forth herein. Among the important factors that could cause actual events to differ materially from those in the forward-looking statements are cash available for distribution, the then current and expected needs and availability of cash to pay MKS’ obligations, and the other factors described in MKS’ Annual Report on Form 10-K for the year ended December 31, 2024 and any subsequent Quarterly Reports on Form 10-Q, as filed with the U.S. Securities and Exchange Commission. MKS is under no obligation to, and expressly disclaims any obligation to, update or alter these forward-looking statements, whether as a result of new information, future events or otherwise after the date of this press release.

MKS Investor Relations Contact:
Paretosh Misra
Vice President, Investor Relations
Telephone: +1 (978) 284-4705
Email: [email protected]

Positive results from the Bleomycin Pulmonary Fibrosis mouse model in vivo study attributing Thykamine™ with anti-fibrotic effects in lungs Compelling results compared to Pirfenidone, a drug used to treat idiopathic pulmonary fibrosis , /PRNewswire/ - Devonian Health Group Inc. ("Devonian" or the "Company") (TSXV: GSD); (OTCQB: DVHGF), a clinical stage corporation focused on developing unique solutions to fibroinflammatory diseases, today announced a potential expanded therapeutic application for Thykamine™, with compelling preclinical data results demonstrating proof of concept efficacy in a well-established animal model of pulmonary fibrosis.

The study investigated the effects of Thykamine™ in bleomycin-induced pulmonary fibrosis (IPF) mouse model, a widely used preclinical tool for studying idiopathic pulmonary fibrosis (IPF) pathophysiology and testing antifibrotic therapies. Pulmonary fibrosis was induced in mice using intranasal bleomycin, a gold-standard and clinically relevant model that closely mirrors key pathological features of human idiopathic pulmonary fibrosis.

Thykamine™ was administered orally at doses of 0.05, 0.1, 0.25, 0.5, and 1 mg/kg, and benchmarked against pirfenidone dosed at 220 mg/kg. Over a 21-day period, animals were monitored for body weight and survival, followed by comprehensive lung assessment. Fibrotic burden was evaluated through lung weight, collagen content, fibrosis-related gene expression, and histopathological scoring.     

In this bleomycin-induced pulmonary fibrosis model, Thykamine™ demonstrated statistically significant antifibrotic activity, while pirfenidone did not reach statistical significance in physiological endpoints. Treatment with Thykamine™ at 0.5 mg/kg significantly reduced lung wet weight and lung tissue index compared with the bleomycin/vehicle group.

Bleomycin exposure led to marked increases in fibrosis (Ashcroft score) and inflammation compared with sham controls. Thykamine™ treatment significantly reversed these pathological changes, reducing both fibrosis and inflammation scores and indicating meaningful improvement in lung morphology.

Consistent with its effects on lung pathology, Thykamine™ at 0.5 mg/kg produced a statistically significant downregulation of key fibrosis- and inflammation-associated genes, including Fn1 (fibronectin), Col1a1, Col3a1, Col6a1, and Col6a3 (collagen isoforms involved in extracellular matrix deposition), Birc5, and the chemokines Ccl2 and Cxcl2 (inflammatory cell recruitment). In parallel, Thykamine™ significantly increased Mmp9, a matrix metalloproteinase associated with extracellular matrix turnover, while reducing Mmp13, a collagenase often linked to progressive tissue injury and inflammation. Together, this gene expression profile is consistent with controlled matrix remodeling and attenuation of fibrotic progression. 

This well-validated model delivers a strong, dose-responsive demonstration of antifibrotic efficacy across multiple translational endpoints, clearly positioning Thykamine™ as a differentiated, next-generation therapeutic candidate in pulmonary fibrosis. The Company plans to present data in an upcoming scientific publication.

"These results represent a major inflection point for Thykamine™," said Dr. Andre P. Boulet, PhD, Chief Executive Officer. "The pulmonary fibrosis data not only confirm and extend the antifibrotic effects we previously observed in mouse MASH model, but also significantly broaden Thykamine™'s mechanism of action. By combining potent anti-inflammatory and anti-fibrotic activity at low doses, Thykamine™ demonstrates clear potential to address the underlying biology of fibro-inflammatory diseases and to serve as a scalable, multi-indication platform with disease-modifying potential."

About Pulmonary Fibrosis1,2,3,4,5

Pulmonary fibrosis, particularly idiopathic pulmonary fibrosis (IPF), is a chronic, progressive, and ultimately fatal interstitial lung disease characterized by irreversible scarring of lung tissue, leading to declining respiratory function and premature mortality. IPF carries a poor prognosis, with median survival estimated at approximately three to five years from diagnosis, highlighting the urgent need for more effective therapies.

Epidemiological studies and recent systematic reviews indicate that the incidence and prevalence of IPF are increasing worldwide, driven in part by aging populations and improved diagnostic awareness. Current estimates suggest an incidence of several cases per 100,000 persons per year, with prevalence rising substantially in older age groups, placing a growing burden on patients and healthcare systems.

Despite the availability of approved antifibrotic therapies, treatment options remain limited and primarily slow disease progression without reversing fibrosis and are often associated with tolerability challenges. As a result, pulmonary fibrosis represents a significant unmet medical need and a rapidly expanding therapeutic market, reinforcing the importance of developing disease-modifying therapies that can more effectively target the underlying fibro-inflammatory drivers of disease.

About Thykamine™

Thykamine™, the first pharmaceutical product issued from Devonian's SUPREX™ platform, is a highly innovative product for the prevention and treatment of health conditions related to fibroinflammation and oxidative stress including ulcerative colitis, atopic dermatitis, psoriasis, rheumatoid arthritis, and other autoimmune disorders. The anti-inflammatory, anti-oxidative and immunomodulatory properties of Thykamine™ have been demonstrated by a considerable number of in vitro and in vivo studies as well as in a Phase IIa clinical study in patients with mild-to-moderate distal ulcerative colitis and in a large Phase II study in adult patients with mild-to-moderate Atopic Dermatitis. Both Thykamine™ and SUPREX™ platform are covered by patents issued in several North American, European and Asian countries.
About Devonian

Devonian Health Group Inc. is a clinical stage pharmaceutical company specializing in the development of drugs for various auto-immune fibroinflammatory conditions with novel therapeutic approaches to targeting unmet medical needs. Devonian's core strategy is to develop prescription drugs for the treatment of inflammatory autoimmune diseases including but not limited to ulcerative colitis and atopic dermatitis. Based on a foundation of over 15 years of research, Devonian's focus is further supported by a U.S. Food and Drug Administration set of regulatory guidelines favoring a more efficient drug development pathway for prescription botanical drug products over those of traditional prescription medicines.

Devonian is also involved in the development of high-value cosmeceutical products leveraging the same proprietary approach employed with their pharmaceutical offerings. Devonian also owns a commercialization subsidiary, Altius Healthcare LP., focused on selling prescription pharmaceutical products in Canada, under license from brand name pharmaceutical companies.

Devonian Health Group Inc. was incorporated in 2015 and is headquartered in Québec, Canada where it owns a state-of-the art extraction facility. Devonian is traded publicly on the TSX Venture Exchange (the "Exchange") (TSXV: GSD) and on OTCQB exchange (OTCQB: DVHGF).

For more information, visit www.groupedevonian.com

References

1.

Golchin N, Patel A, Scheuring J, et al. Incidence and prevalence of idiopathic pulmonary fibrosis: a systematic literature review and meta-analysis. BMC Pulmonary Medicine. 25:378, 2025.

2.

Lederer DJ, and Martinez FJ. Idiopathic Pulmonary Fibrosis. N ENGL J MED, 378: 1811-23, 2018

3.

Chang A, Ry PM and Raghu G. Idiopathic pulmonary fibrosis: aligning murine models to clinical trials in humans. The Lancet Respiratory Medicine 11: P953-955, 2023.

4.

Marinescu D, Wong AW. Epidemiology of idiopathic pulmonary fibrosis: opportunities and hurdles for population-level studies of rare disease. Thorax 2024;79:603-604.

5.

Maher TM. Interstitial Lung Disease, A Review. JAMA, 331(19): 1655-1665, 2024.

Cautionary Note Regarding Forward-Looking Statements

All statements, other than statements of historical fact, contained in this press release including, but not limited to those relating to the Common Shares consolidation; the anticipated post-consolidation trading price of the Common Shares; the potential impact of the consolidation on investor interest and liquidity; the ability to satisfy minimum price or other listing requirements of U.S and other stock exchanges; the impacts in perceived trading price following the consolidation; the ability of the Company to maintain compliance with regulatory requirements following the consolidation; and generally, the above "About Devonian" paragraph, all of which essentially describes the Company's outlook, constitute "forward-looking information" or "forward-looking statements" within the meaning of certain securities laws (collectively, "forward-looking statements"), and are based on expectations, estimates and projections as of the time of this press release. Such forward-looking statements may be identified by the use of words such as "intends", "believes", "expects", or variations (including negative and grammatical variations) of such words and phrases, or state that certain actions, events or results "may", "could", "would", or "will" be taken, occur or be achieved.

Forward-looking statements are necessarily based upon a number of estimates and assumptions that, while considered reasonable by the Company as of the time of such statements, are inherently subject to significant business, economic and competitive uncertainties and contingencies. These estimates and assumptions may prove to be incorrect. Many of these uncertainties and contingencies can directly or indirectly affect, and could cause, actual results to differ materially from those expressed or implied in any forward-looking statements. There can be no assurance that these assumptions will prove to be correct and there can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements.

By their very nature, forward-looking statements involve inherent risks and uncertainties, both general and specific, and risks exist that estimates, forecasts, projections and other forward-looking statements will not be achieved or that assumptions do not reflect future experience. Forward-looking statements are provided for the purpose of providing information about management's expectations and plans relating to the future. Readers are cautioned not to place undue reliance on these forward-looking statements as a number of important risk factors and future events could cause the actual outcomes to differ materially from the beliefs, plans, objectives, expectations, anticipations, estimates, assumptions and intentions expressed in such forward-looking statements. All of the forward-looking statements made in this press release are qualified by these cautionary statements and those made in our other filings with the applicable securities regulators of Canada. The Company disclaims any intention or obligation to update or revise any forward-looking statements or to explain any material difference between subsequent actual events and such forward-looking statements, except to the extent required by applicable law.

Neither the Exchange nor its Regulation Services Provider (as that term is defined in policies of the Exchange) accepts responsibility for the adequacy or accuracy of this release.

SOURCE Devonian Health Group Inc.